Published in AIDS Weekly, May 23rd, 2011
"HIV-infected youth, aged 12 to younger than 25 years, were randomly assigned to one of three treatment arms: Arm 1: Engerix B, 20 mg HBsAg; Arm 2: Engerix B (GlaxoSmithKline, Rixensart, Belgium), 40 mg; and Arm 3: Twinrix (GlaxoSmithKline, Rixensart, Belgium), 20 mg HBsAg combined with 720 ELU hepatitis A antigen. Vaccines were administered at Weeks 0, 4, and 24. Characteristics of evaluable patients (n = 336) at entry were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.